Device aided therapies (DAT) comprising the intrajejunal administration of levodopa/carbidopa intestinal gel (LCIG) and levodopa/carbidopa/entacapone intestinal gel (LECIG), the continuous subcutaneous application of foslevodopa/foscarbidopa or apomorphine infusion (CSAI) and deep brain stimulation (DBS) are used to treat Parkinson’s disease with insufficient symptom alleviation under intensified pharmacotherapy. These DAT significantly differ in their efficacy profiles, indication, invasiveness, contraindications, and potential side effects. Usually, the evaluation of all these procedures is conducted simultaneously at the same point in time. However, as disease progression and symptom burden is extremely heterogeneous, clinical experience shows that patients reach the individual milestones for a certain therapy at different points in their disease course. Therefore, advocating for an individualized therapy evaluation for each DAT, requiring an ongoing evaluation. This necessitates that, during each consultation, the current symptomatology should be analyzed, and the potential suitability for a DAT be assessed. This work represents a critical interdisciplinary appraisal of these therapies in terms of their individual profiles and compares these DAT regarding contraindications, periprocedural considerations as well as their efficacy regarding motor- and non-motor deficits, supporting a personalized approach.

装置辅助治疗（DAT）包括空肠内给予左旋多巴/卡比多巴肠凝胶（LCIG）和左旋多巴/卡比多巴/恩他卡朋肠凝胶（LECIG），连续皮下应用磷左旋多巴/磷卡比巴或阿扑吗啡输注（CSAI）和深部脑刺激（ DBS）用于治疗在强化药物治疗下症状缓解不足的帕金森病。这些 DAT 在功效、适应症、侵袭性、禁忌症和潜在副作用方面存在显着差异。通常，所有这些程序的评估是在同一时间点同时进行的。然而，由于疾病进展和症状负担极其不同，临床经验表明，患者在病程的不同阶段达到某种治疗的个体里程碑。因此，提倡对每个DAT进行个体化治疗评估，需要持续评估。这就需要在每次咨询期间分析当前的症状，并评估 DAT 的潜在适用性。这项工作代表了对这些疗法的个体概况的关键跨学科评估，并比较了这些 DAT 的禁忌症、围手术期考虑因素以及它们对运动和非运动缺陷的疗效，支持个性化方法。